Plasma choline and betaine and neurological function trajectory after acute ischemic stroke

BACKGROUND: Choline metabolism, which participates in various biological processes, has been implicated in the development of atherosclerosis and neurological disorders. However, it remains uncertain whether disruptions in the choline metabolism contribute to longitudinal changes in neurological function. OBJECTIVES: We aimed to prospectively investigate the associations between circulating levels of choline and betaine and neurological function trajectory among patients with ischemic stroke. METHODS: Data came from the China Antihypertensive Trial in Acute Ischemic Stroke (CATIS). Baseline plasma levels of choline and betaine were measured in 933 participants by ultra-high-performance LC-MS/MS. Group-based trajectory model was employed to identify distinct neurological function trajectories, as measured by NIHSS at admission, 14 days or discharge, and at 3-, 12-, and 24-month follow-up. RESULTS: A total of 933 stroke patients were included. Higher choline and betaine levels were generally associated with lower odds of more severe neurological deficit trajectories. Compared with the lowest tertile, the highest choline tertile had adjusted odds ratios (aORs) of 0.68 (95% confidence interval [CI]: 0.44-1.04) for moderate neurological deficits and 0.24 (95% CI: 0.09-0.66) for persistent-severe deficits. Corresponding aORs for betaine were 0.57 (95% CI: 0.37-0.90) and 0.20 (95% CI: 0.08-0.51), respectively. Furthermore, in fully adjusted models, each 1-SD higher log-choline and -betaine was associated with 26% and 28% lower odds of moderate-to-severe neurological deficit. In addition, both choline and betaine improved risk discrimination and reclassification for moderate-to-severe neurological deficit beyond conventional risk factors. CONCLUSIONS: Our study found that lower plasma levels of choline and betaine were generally associated with moderate and persistent-severe neurological function trajectories. TRIAL REGISTRATION: NCT01840072; registration date: 2013-04-13.

Authors

Institutions

Publication Details

Journal
BMC Neurology
Published
2026-06-30
DOI
https://doi.org/10.1186/s12883-026-05132-9
Primary Topic
Neurological Disorders and Treatments
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Plasma choline and betaine and neurological function trajectory after acute ischemic stroke

Yonghong Zhang, Huihui Liu, Chongke Zhong, Mengyue Cao et al.
BMC Neurology
Neurological Disorders and Treatments
article

Plasma choline and betaine and neurological function trajectory after acute ischemic stroke

Yonghong Zhang, Huihui Liu, Chongke Zhong, Mengyue Cao, Churan Zhou, Zhiyi Zong, Tan Xu, Suyang Wu, Heping Guo
article en

Abstract

BACKGROUND: Choline metabolism, which participates in various biological processes, has been implicated in the development of atherosclerosis and neurological disorders. However, it remains uncertain whether disruptions in the choline metabolism contribute to longitudinal changes in neurological function. OBJECTIVES: We aimed to prospectively investigate the associations between circulating levels of choline and betaine and neurological function trajectory among patients with ischemic stroke. METHODS: Data came from the China Antihypertensive Trial in Acute Ischemic Stroke (CATIS). Baseline plasma levels of choline and betaine were measured in 933 participants by ultra-high-performance LC-MS/MS. Group-based trajectory model was employed to identify distinct neurological function trajectories, as measured by NIHSS at admission, 14 days or discharge, and at 3-, 12-, and 24-month follow-up. RESULTS: A total of 933 stroke patients were included. Higher choline and betaine levels were generally associated with lower odds of more severe neurological deficit trajectories. Compared with the lowest tertile, the highest choline tertile had adjusted odds ratios (aORs) of 0.68 (95% confidence interval [CI]: 0.44-1.04) for moderate neurological deficits and 0.24 (95% CI: 0.09-0.66) for persistent-severe deficits. Corresponding aORs for betaine were 0.57 (95% CI: 0.37-0.90) and 0.20 (95% CI: 0.08-0.51), respectively. Furthermore, in fully adjusted models, each 1-SD higher log-choline and -betaine was associated with 26% and 28% lower odds of moderate-to-severe neurological deficit. In addition, both choline and betaine improved risk discrimination and reclassification for moderate-to-severe neurological deficit beyond conventional risk factors. CONCLUSIONS: Our study found that lower plasma levels of choline and betaine were generally associated with moderate and persistent-severe neurological function trajectories. TRIAL REGISTRATION: NCT01840072; registration date: 2013-04-13.

BMC Neurology
Soochow University (CN), Second Affiliated Hospital of Soochow University (CN)
National Natural Science Foundation of China
Good health and well-being
Openalex Percentile: Top 10%
Neurological Disorders and Treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.